Medexus Financial Statements From 2010 to 2026

MDP Stock   2.81  0.03  1.06%   
Medexus Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Medexus Pharmaceuticals' valuation are provided below:
Gross Profit
64 M
Profit Margin
0.0037
Market Capitalization
92.1 M
Enterprise Value Revenue
0.7643
Revenue
104.1 M
We have found one hundred twenty available fundamental ratios for Medexus Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Medexus Pharmaceuticals' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 12th of February 2026, Market Cap is likely to grow to about 102.7 M. Also, Enterprise Value is likely to grow to about 127 M

Medexus Pharmaceuticals Total Revenue

130.81 Million

Check Medexus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medexus Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 34.2 M, Other Operating Expenses of 120.9 M or Operating Income of 9.9 M, as well as many indicators such as Price To Sales Ratio of 0.63, Dividend Yield of 0.0 or PTB Ratio of 1.31. Medexus financial statements analysis is a perfect complement when working with Medexus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Medexus Pharmaceuticals Technical models . Check out the analysis of Medexus Pharmaceuticals Correlation against competitors.

Medexus Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets207.5 M197.6 M84 M
Slightly volatile
Other Current Liabilities64.3 M61.2 M16.9 M
Slightly volatile
Total Current Liabilities117.5 M111.9 M38.9 M
Slightly volatile
Cash28.9 M27.6 M11.8 M
Slightly volatile
Cash And Short Term Investments28.9 M27.6 M11.1 M
Slightly volatile
Common Stock Shares Outstanding17.4 M30.5 M15.9 M
Slightly volatile
Liabilities And Stockholders Equity207.5 M197.6 M83.9 M
Slightly volatile
Other Stockholder Equity8.7 M13.8 M7.8 M
Slightly volatile
Total Liabilities71.8 M137.6 M66 M
Slightly volatile
Total Current Assets97.3 M92.7 M37.9 M
Slightly volatile
Non Current Assets Total110.2 M105 M48.1 M
Slightly volatile
Non Currrent Assets Other11.1 M10.6 M4.5 M
Slightly volatile
Non Current Liabilities Total36.8 M25.7 M30.5 M
Slightly volatile
Short and Long Term Debt Total33.3 M42.8 M25.9 M
Slightly volatile
Property Plant And Equipment Net574.1 K792.4 K452.8 K
Slightly volatile
Current Deferred Revenue48.3 M46 M14.1 M
Slightly volatile
Accounts Payable7.3 M6.6 M5.6 M
Slightly volatile
Net Receivables11.9 M15.3 M9.3 M
Slightly volatile
Inventory42.6 M40.6 M13.7 M
Slightly volatile
Intangible Assets43.7 M82.3 M35.6 M
Slightly volatile
Other Assets10.8 M10.3 M2.9 M
Slightly volatile
Common Stock116 M110.5 M50.4 M
Slightly volatile
Long Term Debt216.3 K227.7 K12.2 M
Slightly volatile
Long Term Debt Total216.3 K227.7 K12.3 M
Slightly volatile
Capital Surpluse9.5 M13.8 MM
Slightly volatile
Cash And Equivalents28.9 M27.6 M10.3 M
Slightly volatile
Property Plant Equipment780.4 K792.4 K474.1 K
Slightly volatile
Net Invested Capital70.3 M102.7 M42.6 M
Slightly volatile
Short and Long Term Debt44.7 M42.5 M13.5 M
Slightly volatile
Other Liabilities30.9 M25.2 M36.5 M
Slightly volatile
Good Will10.8 M11.5 M8.7 M
Slightly volatile
Accumulated Other Comprehensive Income5.1 M6.9 M3.3 M
Slightly volatile
Capital Stock73.1 M110.5 M60 M
Slightly volatile
Property Plant And Equipment Gross2.1 M2.3 M1.8 M
Slightly volatile

Medexus Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative34.2 M32.6 M13.9 M
Slightly volatile
Other Operating Expenses120.9 M115.1 M48.9 M
Slightly volatile
Total Operating Expenses58.4 M55.6 M25.7 M
Slightly volatile
Total Revenue130.8 M124.6 M49.8 M
Slightly volatile
Gross Profit68.3 M65.1 M26.8 M
Slightly volatile
Selling And Marketing Expenses9.3 MM7.9 M
Slightly volatile
Research Development4.8 M9.5 M3.5 M
Slightly volatile
Cost Of Revenue62.5 M59.5 M23.1 M
Slightly volatile
Depreciation And Amortization4.4 M8.3 M3.4 M
Slightly volatile
Interest Expense7.1 M9.4 M5.2 M
Slightly volatile
Interest Income5.2 M7.8 M3.5 M
Slightly volatile
Reconciled Depreciation5.1 M8.3 MM
Slightly volatile

Medexus Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.5 MM6.4 M
Slightly volatile
End Period Cash Flow28.9 M27.6 M10.4 M
Slightly volatile
Stock Based Compensation813.7 K472.6 K652.5 K
Slightly volatile
Depreciation8.7 M8.3 M3.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.630.6610.9406
Slightly volatile
Days Sales Outstanding55.2640.3563.3634
Pretty Stable
Average Payables7.9 M11.3 M6.5 M
Slightly volatile
Stock Based Compensation To Revenue0.00410.00440.0555
Slightly volatile
Capex To Depreciation0.410.442.9328
Slightly volatile
EV To Sales0.760.810.8315
Slightly volatile
Inventory Turnover1.41.321.4433
Slightly volatile
Days Of Inventory On Hand331286500
Slightly volatile
Payables Turnover8.538.133.3797
Slightly volatile
Sales General And Administrative To Revenue0.40.30.3273
Very volatile
Research And Ddevelopement To Revenue0.140.08770.1602
Slightly volatile
Capex To Revenue0.02750.02890.1122
Slightly volatile
Cash Per Share1.121.071.0884
Pretty Stable
Days Payables Outstanding44.1546.48745
Slightly volatile
Intangibles To Total Assets0.330.430.3457
Slightly volatile
Current Ratio0.90.956.8328
Slightly volatile
Receivables Turnover6.869.366.6268
Pretty Stable
Graham Number1.31.791.3663
Slightly volatile
Debt To Equity0.610.641.4038
Slightly volatile
Capex Per Share0.110.0950.1113
Slightly volatile
Average Receivables25.4 M24.2 M10.9 M
Slightly volatile
Revenue Per Share2.343.783.1449
Pretty Stable
Interest Debt Per Share1.771.581.7548
Slightly volatile
Debt To Assets0.420.250.311
Slightly volatile
Operating Cycle407338565
Slightly volatile
Days Of Payables Outstanding44.1546.48745
Slightly volatile
Long Term Debt To Capitalization0.00320.00340.3365
Pretty Stable
Total Debt To Capitalization0.460.370.453
Slightly volatile
Debt Equity Ratio0.610.641.4038
Slightly volatile
Quick Ratio0.510.546.4555
Slightly volatile
Cash Ratio0.270.284.1791
Slightly volatile
Days Of Inventory Outstanding331286500
Slightly volatile
Days Of Sales Outstanding55.2640.3563.3634
Pretty Stable
Fixed Asset Turnover158181146
Very volatile
Debt Ratio0.420.250.311
Slightly volatile
Price Sales Ratio0.630.6610.9406
Slightly volatile
Asset Turnover0.70.720.7474
Slightly volatile
Gross Profit Margin0.640.60.6517
Slightly volatile

Medexus Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap102.7 M71.9 M157.4 M
Slightly volatile
Enterprise Value127 M87 M174 M
Slightly volatile

Medexus Fundamental Market Drivers

Forward Price Earnings4.7304
Cash And Short Term Investments24 M

About Medexus Pharmaceuticals Financial Statements

Medexus Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Medexus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue46 M48.3 M
Total Revenue124.6 M130.8 M
Cost Of Revenue59.5 M62.5 M
Sales General And Administrative To Revenue 0.30  0.40 
Research And Ddevelopement To Revenue 0.09  0.14 
Capex To Revenue 0.03  0.03 
Revenue Per Share 3.78  2.34 
Ebit Per Revenue 0.07  0.07 

Pair Trading with Medexus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Medexus Stock

  0.65CTF-UN Citadel IncomePairCorr

Moving against Medexus Stock

  0.42RVX Resverlogix CorpPairCorr
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medexus Stock

Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.